BDX vs JNJ · P/E 34, rev $21.84B vs P/E 17, rev $49.37B
Becton Dickinson and Company (BDX) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the BDX and JNJ stock pages for the full models.
Not investment advice.